FDA leaders pushed to shorten review of Lilly's orforglipron weight-loss pill

FDA leaders pressed staff internally to shorten the review of Eli Lilly's experimental weight-loss pill, orforglipron, according to internal documents seen by Reuters ^[1]. At one point, the FDA Commissioner's Office asked that the time reviewers spend checking whether a drug application has enough material be cut from 60 days to one week ^[1].

That filing check is an early administrative step, not the final decision on whether a drug is safe and effective. After internal pushback, the Commissioner's Office said it may cut those filing reviews to two or three weeks, depending on an application's complexity ^[1]. Reuters could not confirm whether any change would be implemented, and reported that the situation has been fast moving ^[1].

If a shorter timeline is adopted, Lilly could get a verdict on the pill as early as March 28, ahead of the May 20 date reviewers had set, the documents show ^[1].

Lilly was granted a voucher for orforglipron in November as part of a deal with the Trump administration to lower prices of its weight-loss medicines for government programs and cash-paying patients ^[1]. Lilly CEO David Ricks said that day he expected a March decision ^[1].

Lilly first requested a 60-day period with a target approval date in January, and later argued for a March 30 verdict, saying it had a complete application ready so technical and labeling reviews could run alongside the filing evaluation, according to the documents ^[1]. FDA reviewers kept a 180-day schedule with a May 20 target ^[1].

Under the voucher program, companies must submit chemistry, manufacturing data and draft labeling at least 60 days before a final application, and by law reviewers must assess final drug submissions within 60 days ^[1]. The FDA has said its final review under the voucher scheme takes about two months, producing a total six-month timeline ^[1]. Unless the overall review clock is shortened, the program gives orforglipron the same six-month timeline as the existing priority review process ^[1].

FDA Deputy Chief Medical Officer Mallika Mundkur told staff on Monday that the commissioner's office would like the filing evaluation time reduced from 60 days to one week, the documents show ^[1].

The National Priority Voucher program launched in June and has issued 15 vouchers, promising one- to two-month reviews against a usual 10 to 12 months ^[1]. Other drugs selected include a high-dose version of Novo Nordisk's Wegovy, Disc Medicine's bitopertin for porphyria and Regeneron's DB-OTO for deafness ^[1]. Last week, Commissioner Marty Makary created an internal FDA review council to evaluate drugs under the program and recommend to the principal deputy commissioner; he chairs the group but does not vote ^[1].

A Lilly spokesperson said the drug was chosen because it was innovative, addressed an unmet public health need and aligned with the company's focus on increasing affordability, and said Lilly expects the FDA to conduct a fulsome review of benefit and risk data and make a science-based decision ^[1]. HHS spokesperson Andrew Nixon said the voucher program seeks to address critical national health priorities without compromising safety, adding that FDA reviewers "apply the same standards and processes to all applications" ^[1]. One FDA source, who was not authorized to speak publicly, called the timelines alarming: "The mandate for speed, instead of quality, creates a real possibility that a safety or efficacy issue will not get the meaningful attention it deserves, or that it will be missed entirely" ^[1].

Why it matters for patients

Orforglipron would be an oral medicine rather than an injection, and the timing of any approval affects when that option could reach the market. In a late-stage study, Lilly's pill helped patients lose 12.4% of their body weight ^[1]. In a separate trial, Novo Nordisk's weight-loss pill led to 16.6% weight loss ^[1]. The two were not described as a head-to-head comparison, so those figures are not a direct test of one against the other ^[1]. Novo Nordisk is expected to launch its weight-loss pill in December or January ^[1]. Analysts estimate the obesity treatment market could be worth $150 billion annually by the early 2030s ^[1].

The internal dispute is about how much time reviewers get to check an application before a decision, not about removing required data. Whether a faster filing check would change the agency's final review, or its outcome, has not been disclosed ^[1]. An FDA source quoted in the report raised concerns that speed could crowd out attention to safety or efficacy questions ^[1].

What happens next

• March 28: earliest possible decision date if the new timeline is adopted ^[1].
• March 30: date Lilly argued for ^[1].
• May 20: target decision date FDA reviewers set ^[1].
• December or January: when Novo Nordisk is expected to launch its weight-loss pill ^[1].

It is not yet known what prompted the commissioner's office to seek a shorter filing evaluation, or whether orforglipron would be approved by March ^[1]. Lilly's pill was granted its voucher under a program the FDA describes as having one- to two-month reviews ^[1].